After the UK Parliament voted to reject Prime Minister Theresa May’s proposed Brexit deal with just weeks to go before the United Kingdom’s planned withdrawal from the European Union, the pharmaceutical industry has warned that a no-deal Brexit poses “tangible and immediate threats” to patient safety and public health.
After the UK Parliament voted to reject Prime Minister Theresa May’s proposed Brexit deal with just weeks to go before the United Kingdom’s planned withdrawal from the European Union, the pharmaceutical industry has warned that a no-deal Brexit poses “tangible and immediate threats” to patient safety and public health.
That warning came from the European Federation of Pharmaceutical Industries and Associations (EFPIA) in a statement issued after May’s deal was voted down. EFPIA’s director general, Nathalie Moll, said in a statement that “Now is the time for policy makers in the [United Kingdom] and the [European Union] to put politics aside and put measures in place to prevent patients being harmed by the consequences of Brexit. In particular, from disruption to the supply of medicines including from transport delays at the border and where the development, manufacture, packaging, safety testing, and regulation of the medicine no longer benefits from mutual recognition.”
EFPIA called on negotiators to agree to a set of key actions to protect patients, such as exempting medicines and clinical trial materials from customs and border checks, coordinating fast-track lanes for the transport of medicines into ports, and potentially exempting active pharmaceutical ingredients from border checks to ensure that drug manufacturing can continue with limited disruption.
The Association of the British Pharmaceutical Industry (ABPI) also called on the UK government to bring clarity to the industry. In a statement, Mike Thompson, chief executive of ABPI, said, “We reiterate that ‘no deal’ would prove to be extremely challenging. With time running out, we hope Parliament will come together and quickly find a solution to the stalemate and reassure patients that medicines will not be disrupted come March 2019.”
Meanwhile, drug companies are making their own plans to avoid disruptions to the flow of medicines in the event of a no-deal Brexit. This week, Bloomberg reported that Novo Nordisk has begun to book air freight slots for its medicines so that insulin can be flown into the United Kingdom (which does not manufacture any of its own analogue or synthetic human insulin) if necessary. Fellow insulin maker Sanofi is currently testing alternative routes (from the Netherlands to the eastern coast and from France to the south) into the United Kingdom.
Even before embracing such options, drug makers had begun to stockpile their products after UK Health Secretary Matt Hancock advised that trade delays at the border could last for as long as 6 months. The specific drugs that are being stockpiled are not known, however; as The Guardian reported in December 2018, the UK government has demanded that pharmaceutical companies and organizations that are working in concert with the government to maintain supplies of their products sign nondisclosure agreements that prevent them from disclosing any details of their contingency plans.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.